PF03716556
PF03716556 Basic information
- Product Name:
- PF03716556
- Synonyms:
-
- 8-[[(4R)-3,4-Dihydro-5-Methyl-2H-1-benzopyran-4-yl]aMino]-N-(2-hydroxyethyl)-N,2-diMethyliMidazo[1,2-a]pyridine-6-carboxaMide
- N-(2-Hydroxyethyl)-N,2-diMethyl-8-{[(4R)-5-Methyl-3,4-dihydro-2H-chroMen-4-yl]aMino}iMidazo[1,2-a]pyridine-6-carboxa
- (R)-N-(2-hydroxyethyl)-N,2-dimethyl-8-(5-methyl-3,4-dihydro-2H-chromen-4-ylamino)H-imidazo[1,2-a]pyridine-6-carboxamide
- 8-[[(4R)-3,4-Dihydro-5-methyl-2H-1-benzopyran-4-yl]amino]-N-(2-hydroxyethyl)-N,2-dimethylimidazo[1,2-a]pyridine-6-carboxamide PF 03716556
- [N-(2-Hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide]
- PF03716556
- PF 3716556
- PF-3716556;PF-03716556; PF03716556
- CAS:
- 928774-43-0
- MF:
- C22H26N4O3
- MW:
- 394.47
- Product Categories:
-
- Amines
- Aromatics
- Heterocycles
- Inhibitors
- Intermediates & Fine Chemicals
- Pfizer Compounds
- Pharmaceuticals
- Mol File:
- 928774-43-0.mol
PF03716556 Chemical Properties
- Melting point:
- 143-145°C
- Density
- 1.30
- storage temp.
- Keep in dark place,Inert atmosphere,2-8°C
- solubility
- DMSO: ≥10mg/mL
- form
- powder
- pka
- 14.18±0.10(Predicted)
- color
- white to tan
PF03716556 Usage And Synthesis
Chemical Properties
Light Tan Solid
Uses
A novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease.
Biological Activity
the gastric h+,k+-atpase, which is responsible for gastric acid secretion, is a p2-type atpase located in the apical membrane of parietal cells. inhibition of the h+,k+-atpase is currently the most effective way to control gastric acid secretion and remains an attractive target for the medical treatment of acidrelated diseases. pf-03716556 is a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease.
in vitro
pf-03716556 demonstrated 3-fold greater inhibitory activity than revaprazan, the only acid pump antagonist that has been available on the market, in ion-tight assay. kinetics experiments revealed that pf-03716556 has a competitive and reversible mode of action [1].
in vivo
pf-03716556 did not display any species differences, exhibiting highly selective profile including the canine kidney h+,k+-atpase. in addition, more rapid onset of action than omeprazole and 3-fold greater potency than revaprazan were observed in ghosh-schild rats and heidenhain pouch dogs [2].
IC 50
in porcine ion-tight membrane vesicles, pf-03716556 inhibited h+,k+-atpase activity in a concentration-dependent manner, with a pic50 value of 7.095 ± 0.077 at ph 7.4.
storage
-20°C
References
[1] mori h, tonai-kachi h, ochi y, taniguchi y, ohshiro h, takahashi n, aihara t, hirao a, kato t, sakakibara m, kurebayashi y. n-(2-hydroxyethyl)-n,2-dimethyl-8-{[(4r)-5-methyl-3,4- dihydro-2h-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (pf-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease. j pharmacol exp ther. 2009;328(2):671-9.
PF03716556Supplier
- Tel
- sales@boylechem.com
- Tel
- 010-82848833 400-666-7788
- jkinfo@jkchemical.com
- Tel
- 021-50135380
- shchemsky@sina.com
- Tel
- 86-0571-85151182
- Tel
- 0411-62910999 13889544652
- sales@meilune.com